U.S. markets close in 20 minutes
  • S&P 500

    4,204.74
    -27.86 (-0.66%)
     
  • Dow 30

    34,874.85
    +97.09 (+0.28%)
     
  • Nasdaq

    13,451.98
    -300.26 (-2.18%)
     
  • Russell 2000

    2,221.59
    -50.04 (-2.20%)
     
  • Crude Oil

    64.82
    -0.08 (-0.12%)
     
  • Gold

    1,837.10
    +5.80 (+0.32%)
     
  • Silver

    27.42
    -0.06 (-0.23%)
     
  • EUR/USD

    1.2148
    -0.0021 (-0.17%)
     
  • 10-Yr Bond

    1.6020
    +0.0250 (+1.59%)
     
  • GBP/USD

    1.4132
    +0.0143 (+1.02%)
     
  • USD/JPY

    108.7940
    +0.2120 (+0.20%)
     
  • BTC-USD

    56,280.55
    -1,147.48 (-2.00%)
     
  • CMC Crypto 200

    1,500.63
    -60.67 (-3.89%)
     
  • FTSE 100

    7,123.68
    -6.03 (-0.08%)
     
  • Nikkei 225

    29,518.34
    +160.52 (+0.55%)
     

Have Insiders Been Buying Helix BioPharma Corp. (TSE:HBP) Shares This Year?

  • Oops!
    Something went wrong.
    Please try again later.
Simply Wall St
·3 min read
  • Oops!
    Something went wrong.
    Please try again later.

We often see insiders buying up shares in companies that perform well over the long term. On the other hand, we'd be remiss not to mention that insider sales have been known to precede tough periods for a business. So we'll take a look at whether insiders have been buying or selling shares in Helix BioPharma Corp. (TSE:HBP).

Do Insider Transactions Matter?

It's quite normal to see company insiders, such as board members, trading in company stock, from time to time. However, rules govern insider transactions, and certain disclosures are required.

We would never suggest that investors should base their decisions solely on what the directors of a company have been doing. But equally, we would consider it foolish to ignore insider transactions altogether. As Peter Lynch said, 'insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise.

Check out our latest analysis for Helix BioPharma

The Last 12 Months Of Insider Transactions At Helix BioPharma

Over the last year, we can see that the biggest insider purchase was by insider Jerzy Wilczewski for CA$6.2m worth of shares, at about CA$0.46 per share. Even though the purchase was made at a significantly lower price than the recent price (CA$1.34), we still think insider buying is a positive. Because the shares were purchased at a lower price, this particular buy doesn't tell us much about how insiders feel about the current share price.

You can see the insider transactions (by individuals) over the last year depicted in the chart below. By clicking on the graph below, you can see the precise details of each insider transaction!

TSX:HBP Recent Insider Trading May 20th 2020
TSX:HBP Recent Insider Trading May 20th 2020

There are plenty of other companies that have insiders buying up shares. You probably do not want to miss this free list of growing companies that insiders are buying.

Insider Ownership of Helix BioPharma

Many investors like to check how much of a company is owned by insiders. We usually like to see fairly high levels of insider ownership. It appears that Helix BioPharma insiders own 16% of the company, worth about CA$29m. We've certainly seen higher levels of insider ownership elsewhere, but these holdings are enough to suggest alignment between insiders and the other shareholders.

So What Do The Helix BioPharma Insider Transactions Indicate?

It doesn't really mean much that no insider has traded Helix BioPharma shares in the last quarter. However, our analysis of transactions over the last year is heartening. Insiders do have a stake in Helix BioPharma and their transactions don't cause us concern. While we like knowing what's going on with the insider's ownership and transactions, we make sure to also consider what risks are facing a stock before making any investment decision. While conducting our analysis, we found that Helix BioPharma has 2 warning signs and it would be unwise to ignore these.

If you would prefer to check out another company -- one with potentially superior financials -- then do not miss this free list of interesting companies, that have HIGH return on equity and low debt.

For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions, but not derivative transactions.

Love or hate this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com.

This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Thank you for reading.